Another successful US FDA Inspection with Positive Outcome

Recently, US FDA Inspected BECRO for one more time, and the Outcome of the Inspection was again Positive with No Observations. The aim of the FDA Inspection was to determine whether the activities and procedures of BECRO complied with 21 CFR Part 320 – Bioavailability and Bioequivalence (BE). In particular, FDA conducted this inspection to

Invitation to BECRO’s Stand 24D44 at CPhI Milan 2024

BECRO is participating as Exhibitor at CPhI Milan 2024 (8-10 October), Stand 24D44. BECRO is specialized in the conduct of BECRO offers clinical trials services all the way from study set up to submission. In addition, BECRO specializes in drafting modules of CDT and CERs for Medical Devices, and in preparing CDT and CDISC for

Invitation to BECRO’s Stand at CPhI Barcelona 2023

CPhI Barcelona 2023 BECRO is participating as Exhibitor at CPhI Barcelona 2023 (24-26 October), Stand 80E40, zone API. BECRO offers clinical trials services all the way from study set up to submission. In addition, BECRO specializes in drafting modules of CDT and CERs for Medical Devices, and in preparing CDT and CDISC for US FDA submissions. BECRO was

Invitation to BECRO’s Stand at CPhI Frankfurt 2022

BECRO is participating as Exhibitor at CPhI Worldwide Frankfurt 2022 (1-3 November), Stand 91A68, Hall 9.1. BECRO offers clinical trials services all the way from study set up to submission. In addition, BECRO specializes in drafting modules of CDT and CERs for Medical Devices, and in preparing CDT and CDISC for US FDA submissions. BECRO

FDA Inspected

BECRO Ltd was inspected by US FDA, recently, and the outcome of the inspection was positive

Accessibility Toolbar